Find research datasets worth reusing

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopi

ClinicalTrials.gov study NCT02631876. IPD Sharing: Not stated. Countries: 13. Publications: 1.

Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.

ClinicalTrials.gov study NCT01813721. IPD Sharing: Not stated. Countries: 11. Publications: 2.

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

ClinicalTrials.gov study NCT01094548. IPD Sharing: Not stated. Countries: 1. Publications: 1.

Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

ClinicalTrials.gov study NCT03101748. IPD Sharing: Not stated. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

ClinicalTrials.gov study NCT00134017. IPD Sharing: NO. Countries: 1. Publications: 1.

PET-MR for Prediction and Monitoring of Response to Neoadjuvant Chemotherapy in Breast Cancer

ClinicalTrials.gov study NCT01190566. IPD Sharing: Not stated. Countries: 1. Publications: 1.

publicAug 2025View details →

dryad36/100

Physical activity is associated with exercise capacity among patients undergoing chemotherapy: a pilot randomized controlled trial

Open the record for dataset details and reuse information.

opencc-by-4.0Feb 2020View details →

Schistosomiasis and soil-transmitted helminthiasis preventive chemotherapy: Adverse events in children from 2 to 15 years in Bengo province, Angola - Dataset

In the context of a targeted drug administration, between December 2012 and September 2013, we conducted two surveys after co-administrating single oral doses of praziquantel and albendazole tablets to children 2 to 15 years of age. About 24 hours after each treatment, participants answered a questionnaire about adverse events. At baseline, 605 children (55.0% male; mean age: 9.7 years) were treated; 460 were interviewed and 257 (55.9%) reported at least one adverse event, 62.3% (160/257) of children being infected with schistosoma haematobium. After six months of treatment, among 339 children surveyed, 184 (54.3%) reported adverse events, with 49.5% (91/184) of infected children. Adverse events were most common in preschool-aged children, with no significant difference between genders. The most frequent adverse events in the two surveys were abdominal pain (18.5%, 25.7%), headache (20.9%, 23.0%) and dizziness (15.7%, 19.8%). Children aged 12 to 15 years (adjusted OR=0.40, p=0.040) and those with mixed infection (adjusted OR=0.04, p=0.011) had lower odds of adverse events. After the second treatment, those with heavy infection (adjusted OR=2.72, p=0.018) and aged 9-11 years (adjusted OR=2.01, p=0.049) had significantly fewer adverse events. About 2.0% of children experienced severe adverse events.

opencc-zeroJan 2020View details →

Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for RAS wild-type metastatic colorectal cancer patients based on the TAILOR trial

Objectives Cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) is superior to FOLFOX-4 alone as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer (wt mCRC), with significantly improved survival benefit by TAILOR, an open-label, randomized, multicentre, phase III trial. Nevertheless, the cost-effectiveness of these two regimens remains uncertain. The following study aims to determine whether cetuximab combined with FOLFOX-4 is a cost-effective strategy for specific RAS wt mCRC patients in China. Design A combined decision tree and Markov model with three health states (stable, progressive and dead) was constructed to simulate a hypothetical cohort of patients with RAS wt mCRC. The health outcomes and utility scores were derived from the TAILOR trial and previously published sources, respectively. Costs were calculated with reference to the Chinese societal perspective. A lifetime horizon was used. Univariate and probabilistic sensitivity analyses were carried out to test the robustness of the model results. Participants The included patients were newly diagnosed Chinese patients with fully RAS wt mCRC. Interventions Either cetuximab plus FOLFOX-4 or FOLFOX-4 alone as a first-line treatment. Main outcome measures The primary outcomes are costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs). Results Baseline analysis showed that the addition of cetuximab increased the QALYs by 0.383, while an increase of $62,947 was observed in relation to FOLFOX-4 chemotherapy. This led to an incremental cost-effectiveness ratio (ICER) of $164,044/QALY. Sensitivity analysis showed that across the wide variation in parameters, the ICER exceeded the willingness-to-pay threshold of $28,106/QALY, which was three times the per capita GDP in China. Conclusions Despite the survival benefit, cetuximab combined with FOLFOX-4 is not a cost-effective treatment for the first line treatment of patients with RAS wt mCRC in China.

opencc-zeroDec 2015View details →

Data from: Neoadjuvant and concurrent chemotherapy have varied impacts on the prognosis of patients with the ascending and descending types of nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

Purpose: To compare the outcomes of patients with ascending type (T4&N0-1) and descending type (T1-2&N3) of nasopharyngeal carcinoma (NPC) treated with concurrent chemoradiotherapy (CCRT), neoadjuvant chemotherapy (NACT) + intensity-modulated radiotherapy (RT) or NACT + CCRT. Methods: Retrospective analysis of 839 patients with ascending or descending types of NPC treated at a single institution between October 2009 to February 2012. CCRT was delivered to 236 patients, NACT + RT to 302 patients, and NACT + CCRT to 301 patients. Results: The 4-year overall survival rate, distant metastasis-free survival rate, local relapse-free survival rate, nodal relapse-free survival rate, loco-regional relapse-free survival rate, and progression free survival rate were 75.2% and 73.4% (P = 0.114), 85.7% and 74.1% (P = 0.008), 88.8% and 97.1% (P = 0.013), 96.9% and 94.1% (P = 0.122), 86.9% and 91.2% (P = 0.384), 73.7% and 66.2% (P = 0.063) in ascending type and descending type. Subgroup analyses indicated that NACT + RT significantly improved distant metastasis-free survival rate and progression-free survival rate when compared with CCRT in the ascending type, and there were no significant differences between the survival curves of NACT +RT and NACT + CCRT. For descending type, there were no significant differences among the survival curves of NACT +RT, CCRT, and NACT + CCRT groups, and the survival benefit mainly came from CCRT. Conclusions: Compared with NACT + CCRT or CCRT, NACT + RT may be a reasonable approach for ascending type; Although concurrent chemotherapy was effective in descending type, NACT + CCRT may be a more appropriate strategy for descending type.

opencc-zeroMay 2022View details →

Tumor RNAseq and nCounter for ERY974 monotherapy and/or combination with chemotherapy

We examined pharmacodynamic (PD) of ERY974, CD3 and GPC3-targeting T cell bispecific antibody (TRAB), in tumors of huminized/NOG mice administered with ERY974 and/or chemotherapy. First, we examined the RNAsea data of ERY974 monothrapy for tumors of PC10, NCI-H446, MKN45, and MKN74 of humanized/NOG mice. We found that gene expression related with immune cells at baseline is correlated with efficacy of ERY974. Then,we examined the PD of ERY974 combined with chemotherapy (paclitaxel, cisplatin and capecitabine). In NCI-H446, a representative of non-inflamed-tumor, we examined the tumor RNA of huminized/NOG mice administered with ERY974 and/or paclitaxel, or cisplatin. In MKN45, a representative of non-inflamed-tumor, we examined the tumor RNA of huminized/NOG mice administered with ERY974 and/or capecitabine. For capecitabine combination, we firstly examined the suitable timing among day 3,7,and 14 when combination effect was cleary observed, and found that day 14 is the most suitable timing. From all the data, we found that combination of chemotherpay increased ERY974-induced gene expression related with T cell marker and T cell activation. To examine if our findings are observed in other TRABs in common, we parepred for the EGFR-TRAB, and examined the RNA analysis of MKN45 tumor of huminized/NOG mice administred with EGFR-TRAB and/or paclitaxel. We confirmed that paclitaxel increased EGFR-TRAB-induced gene expression related with T cell marker and T cell activation. We concluded that combination of TRABs with chemotharpy is suitable strategy to erradicate non-inflamed tumors.

opencc-by-4.0Aug 2021View details →

NanoString dataset for study: Dynamic changes in the NK-, Neutrophil-, and B-cell immunophenotypes relevant in high metastatic risk post neoadjuvant chemotherapy–resistant early breast cancers

Pre-processed DSP and mRNA abundance datasets used in this study.

opencc-by-4.0Mar 2018View details →

Adverse effects of chemotherapy on the teeth and surrounding tissues of children with cancer: a systematic review with meta-analysis

Datasets of the journal publication.

opencc-by-4.0Aug 2018View details →

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia: A report from the TARGET initiative

Acute myeloid leukemias (AML) are characterized by distinct mutations of tumor suppressor and oncogenes, involving distinct genes in adults and children.  While certain mutations have been associated with the increased risk of AML relapse the genomic landscape of primary chemotherapy resistant AML is not well defined. As part of the TARGET initiative, we performed whole-genome DNA sequencing, transcriptome RNA, and miRNA sequencing analysis of pediatric AML with failure of induction chemotherapy. We identified three distinct genetic groups of patients with induction failure, including those with NUP98 rearrangements, somatic mutations of WT1, ELF1, KMT2C, MLLT10, and additional recurrent gene mutations, fusions, and structural rearrangements, some of which have been observed in other malignancies. Comparison of specimens before and after chemotherapy revealed distinct and invariant gene expression programs. While exhibiting gross therapy resistance, these leukemias had diverse forms of clonal evolution upon chemotherapy exposure. This included selection for mutant alleles of FRMD8, DHX32, PIK3R1, SHANK3, MKLN1, as well as persistence of WT1 and TP53 mutant clones, and elimination or contraction of FLT3, PTPN11, and NRAS mutant clones. These findings delineate genetic mechanisms of primary chemotherapy resistance in pediatric AML, which should inform improved approaches for its diagnosis and therapy.

opencc-by-4.0Aug 2024View details →

A multimodal and fully automated system for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer

Open the record for dataset details and reuse information.

opencc-zeroJul 2019View details →

Data from: Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study)

Objective: Few data regarding the incidence of cancer-associated thromboembolism (TE) are available for Asian populations. We investigated the incidence of TE (TEi) and its risk factors among gastric and colorectal cancer (GCC) patients who received chemotherapy in a daily practice setting. Design: A retrospective cohort study. Setting: A single institutional study that used data from Sapporo City General Hospital, Japan, on patients treated between January 2008 and May 2015. Participants: Five hundred Japanese GCC patients who started chemotherapy from January 2008 to May 2015. Primary and secondary outcome measures: TE was diagnosed by reviewing all the reports of contrast-enhanced computed tomography (CT) performed during the follow-up period. All types of thrombosis detected by CT or additional imaging tests, such as venous TE, arterial TE, and cerebral infarction, were defined as TE. Medical records of all identified patients were reviewed and potential risk factors for TE including clinicopathological backgrounds were collected. We defined the following patients as 'active cancer'; patients with unresectable advanced GCC, cancer recurrence during or after completing adjuvant (Adj) chemotherapy, and/or presence of other malignant tumours. Results: Of the 500 patients, 70 patients (14.0%) developed TE during the follow-up period. TEi was 9.2% and 17.3% in gastric and colorectal cancer patients, 18.1% and 3.5% in active and non-active cancer patients, and 24.0% and 12.9% in multiple and single primary, respectively. Multivariate logistic regression analysis showed that colorectal cancer (odds ratio [OR], 2.371; 95% confidence interval [CI], 1.328 to 4.233), active cancer (OR 7.593; 95% CI 2.950 to 19.543), and multiple primary (OR 2.527; 95% CI 1.189 to 5.370) were independently associated with TEi. Conclusion: TEi was 14.0% among Japanese GCC patients received chemotherapy, and was significantly higher among patients with colorectal cancer, active cancer, and multiple primary than among those with gastric cancer, non-active cancer, and single primary, respectively.

opencc-by-4.0Sep 2022View details →

Fatty acids homeostasis during fasting predicts protection from chemotherapy toxicity

Fasting exerts beneficial effects in mice and humans, including protection from chemotherapy toxicity. To explore the involved mechanisms, we collect blood from humans and mice before and after 36 or 24 hours of fasting, respectively, and measure lipid composition of erythrocyte membranes, circulating micro RNAs (miRNAs), and RNA expression at peripheral blood mononuclear cells (PBMCs). Fasting coordinately affects the proportion of polyunsaturated versus saturated and monounsaturated fatty acids at the erythrocyte membrane; and reduces the expression of insulin signaling-related genes in PBMCs. When fasted for 24 hours before and 24 hours after administration of oxaliplatin or doxorubicin, mice show a strong protection from toxicity in several tissues. Erythrocyte membrane lipids and PBMC gene expression define two separate groups of individuals that accurately predict a differential protection from chemotherapy toxicity, with important clinical implications. Our results reveal a mechanism of fasting associated with lipid homeostasis, and provide biomarkers of fasting to predict fasting-mediated protection from chemotherapy toxicity.

opencc-by-4.0Mar 2023View details →

Immune Checkpoint Inhibitor, Nivolumab, Combined with Chemotherapy Improved the Survival of Unresectable Ad-vanced and Metastatic Esophageal Squamous Cell Carcinoma: a real world experience

Figure S1 the detail of treatments. Blue arrow means this patient was still alive at the latest date of follow up. Hollow circle means this patient die. The others were lose follow up at the latest date of follow up. Figure S2 progression free survival (PFS) of patients received immunotherapy, including 5 nivolumab and chemotherapy and 1 dual immune check point inhibitor, on different PD-L1 tumor cells (TC) expression. (A) divided by PD-L1 TC <1% or ≧1%. (B)divided by PD-L1 TC <10% or ≧10%.

openbsd-2-clause-netbsdMar 2023View details →

Simulation models for cancer immunotherapy and chemotherapy trials

This repository contains code and data related to the following manuscript: In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome Jeroen H.A. Creemers, Kit C.B. Roes, Niven Mehra, Carl G. Figdor, I. Jolanda M. de Vries, Johannes Textor medRxiv 2021.09.09.21263319; doi: <a href="https://doi.org/10.1101/2021.09.09.21263319">https://doi.org/10.1101/2021.09.09.21263319</a> The manuscript (the revised version of which can be found in this repository) describes three simulation models for cancer patient survival data with different immunotherapy treatments. This repository contains the source code of the simulation models, which are written in C++, as well as an R wrappers using the Rcpp package. These can be found in the directory models/TumorImmuneModels/. There is also a web-based implementation, written in JavaScript, available at <a href="https://computational-immunology.org/models/immunotherapy-trials/">https://computational-immunology.org/models/immunotherapy-trials/</a>. Finally, see the folder "figures" for the code used to perform the analyses and generate the figures shown in the manuscript.

ClinicalTrials.gov32/100

Induction Chemotherapy for Locally Advanced Rectal Cancer

ClinicalTrials.gov study NCT04838496. IPD Sharing: Not stated. Countries: 1. Publications: 1.